Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The presentation is scheduled for September 30, 2025, at 12:00 PM EST.

CEO and Chairman Robert Bitterman will discuss the company's proprietary INTASYL gene silencing technology and provide updates on their ongoing clinical trial of PH-762 for skin cancer treatment. The company recently reported positive interim safety and efficacy results from the Phase 1b dose escalation clinical trial.

Insights

Biotech Analyst

Phio's Phase 1b trial for PH-762 showing positive interim results represents meaningful progress for their skin cancer treatment pipeline.

Phio Pharmaceuticals' announcement contains some noteworthy clinical progress embedded within what's primarily a roadshow announcement. The company disclosed positive interim safety and efficacy results from their ongoing Phase 1b dose escalation trial of PH-762 for skin cancer treatment. This represents meaningful progress for their lead compound utilizing their proprietary INTASYL siRNA technology platform.

The INTASYL platform is designed to silence specific genes that contribute to cancer progression, potentially offering a novel approach to cancer treatment. For a clinical-stage biotech company like Phio, positive early-stage results are particularly significant as they validate both the specific compound (PH-762) and potentially their broader technology platform.

While the announcement lacks specific data points regarding the interim results (such as response rates, duration of response, or specific safety metrics), the characterization as "positive" suggests the trial is meeting its primary endpoints at this stage. Phase 1b trials primarily assess safety and tolerability while exploring preliminary efficacy signals, so positive results here would typically enable progression to more advanced clinical trials.

The upcoming presentation by CEO Robert Bitterman may provide more granular data on these interim results. The live Q&A format also suggests management's confidence in addressing potential investor questions about their clinical progress. For a small clinical-stage biotech, maintaining this momentum is crucial for both clinical advancement and securing additional funding for later-stage development.

Registration Link Below for September 30, 2025 12 PM EST Presentation and Live Q&A

King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL^® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the on-going Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer.

Phio's presentation and live Q&A will take place on Tuesday, Sept 30, 2025, at 12:00 PM EST in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.

"All stakeholders, investors, and other individual followers are invited to join this event to learn more about Phio Pharmaceuticals and our continuing pursuit of innovative pathways towards a cancer free future using our INTASYL technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

REGISTER HERE: Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications

Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL^® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

For additional information, visit the Company's website, www.phiopharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells, the potential for additional potential applications across the INTASYL portfolio, expectations regarding timing of enrollment, and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.  

These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control.  Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.  

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel: (416)-644-2020 or (212)-812-7680
www.renmarkfinancial.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267362

FAQ

When is Phio Pharmaceuticals (NASDAQ: PHIO) presenting at the Renmark Virtual Non-Deal Roadshow?

Phio Pharmaceuticals will present on Tuesday, September 30, 2025, at 12:00 PM EST.

What will be discussed during Phio Pharmaceuticals' (PHIO) presentation?

The presentation will cover updates on their proprietary INTASYL gene silencing technology and progress on the ongoing clinical trial of PH-762 for skin cancer treatment.

Who will be presenting at the Phio Pharmaceuticals (PHIO) Virtual Non-Deal Roadshow?

Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals, will be presenting.

How can investors access Phio Pharmaceuticals' (PHIO) Virtual Non-Deal Roadshow presentation?

Investors can register through the Renmark Financial Communications website, and a replay will be available at www.renmarkfinancial.com/vndrs.

What recent clinical trial results has Phio Pharmaceuticals (PHIO) reported?

Phio recently reported positive interim safety and efficacy results from their Phase 1b dose escalation clinical trial of PH-762 for skin cancer treatment.